Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.57 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744020 | 0.86 | ALDH1A1 (0.51) | HCRTR1HCRTR2ALDH1A1MAPK1MAPT | |
| SCHEMBL5156886 | 0.85 | HCRTR1 (0.67) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL5152814 | 0.83 | HCRTR1 (0.60) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL765322 | 0.83 | HCRTR1 (0.74) | HCRTR1HCRTR2 | |
| SCHEMBL5149621 | 0.82 | MEN1 (0.58) | HCRTR1HCRTR2ALDH1A1MAPK1MAPT | |
| SCHEMBL744887 | 0.82 | HCRTR2 (0.52) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL744486 | 0.81 | HCRTR1 (0.79) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL5155080 | 0.79 | CACNA1B (0.52) | HCRTR1HCRTR2ALDH1A1MAPK1MAPT | |
| SCHEMBL5154879 | 0.78 | KMT2A (0.65) | HCRTR1HCRTR2ALDH1A1MAPK1MAPT | |
| SCHEMBL5151355 | 0.77 | MAPT (0.56) | HCRTR1HCRTR2MAPK1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | HCRTR1 1608/4885HCRTR2 194/4885ALDH1A1 3381/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HCRTR1 2195/4885HCRTR2 251/4885ALDH1A1 1370/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HCRTR1 2195/4885HCRTR2 251/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.